CSL Ltd (ASX: CSL) shares have already recovered strongly from their lows, but they remain well below $250.

At around $182.00 today, the healthcare giant would need to rise approximately 37% to get there.

So what would need to happen for CSL shares to return to $250?

The earnings outlook is positive

I think earnings growth can provide part of the answer.

Consensus forecasts point to earnings per share (EPS) of $8.99 in FY27, $9.48 in FY28, and $10.08 in FY29.

That is not explosive growth, but it would represent steady progress over the next few years.

At the current share price, CSL trades on a PE ratio of roughly 20 times forecast FY27 earnings.

That multiple falls to around 19 times FY28 earnings and just over 18 times the FY29 estimate.

For me, that leaves room for the share price to climb if CSL delivers on those forecasts.

What would CSL be worth at $250?

At $250, the shares would trade at almost 28 times forecast FY27 earnings.

That would be a significant premium to today’s valuation and would require investors to become much more confident about the outlook.

But the hurdle falls as earnings grow.

Against FY28 EPS of $9.48, a $250 share price would represent around 26 times earnings. Using the FY29 forecast of $10.08, the multiple falls to just under 25 times.

That looks more achievable to me.

CSL would still need a re-rating from today’s valuation, but the company would also have higher earnings supporting that share price.

What would need to go right?

For me, the first requirement would be a continued recovery in CSL’s underlying performance.

Demand for immunoglobulins remains central to the CSL Behring story. If that demand stays strong and CSL can continue increasing the amount of plasma available to meet it, there should be room for revenue and earnings to keep growing.

The economics of collecting that plasma are also important.

I would want to see continued improvements in collection efficiency and plasma yields, because producing more finished product from the collection network can help margins as well as volumes.

That could be particularly important for rebuilding profitability in CSL Behring after the pressure seen over recent years.

Product development could provide another leg of growth.

CSL has a substantial research and development pipeline, and successful new products or expanded uses for existing therapies could create additional earnings streams beyond the company’s established franchises.

If the company can combine strong immunoglobulin demand, better plasma economics, margin improvement, and contributions from newer products, the current consensus earnings trajectory starts to look much more achievable.

And if investors become convinced that the recovery is sustainable, I think they could become willing to pay a higher multiple for those earnings again.

Foolish takeaway

I think $250 is achievable for CSL shares, but it will need more than time.

The company needs to keep growing immunoglobulin volumes, improve plasma collection economics, rebuild margins, and make progress with newer products.

If that translates into EPS of around $10 by FY29, a $250 share price would imply a PE ratio of roughly 25 times.

I think that is possible if CSL can restore confidence in its growth story.

The post What would it take for CSL shares to return to $250? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Fortescue, Westpac, CSL shares
• Experts name 3 popular ASX 200 shares to buy this week
• Here are the top 10 ASX 200 shares today
• 3 cheap ASX shares I would buy now
• Buy, hold, sell: CBA, BHP, CSL shares

Motley Fool contributor Grace Alvino has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX All Ords Index (ASX: XAO) shares are down 3% over 12 months.

On The Bull this week, Mark Gardner from MPC Markets shares his insights on three stocks.

Greatland Resources Ltd (ASX: GGP)

The Greatland Resources share price is up 40% over 12 months. 

Gardner has a buy call on this ASX gold mining share. 

He said: 

Greatland is moving into mid-tier gold and copper production.

GGP produced 328,987 ounces of gold and 14,594 tonnes of copper in full year 2026. The company beat production and cost guidance.

Net profit after tax of $862 million was up 156 per cent on the prior corresponding period.

The shares have fallen on weaker production guidance in full year 2027.

GGP offers an appealing entry price. In our view, the market is too focused on a weaker guidance rather than funded growth.

Telix Pharmaceuticals Ltd (ASX: TLX)

The Telix Pharmaceuticals share price is up 7% over 12 months. 

Gardner has a hold rating on this ASX healthcare share. 

He explained: 

The US Food and Drug Administration recently approved the company’s brain cancer imaging drug Pixclara.

TLX shares soared on the news, but we believe the approval is largely priced in at this point.

However, the underlying business is in good shape. Group revenue of $US477 million in the first half of 2026 was up 22 per cent on the prior corresponding period.

The group gross margin of 55 per cent was up 2 per cent year-on year. The company maintained a cash balance of $US252 million at June 30, 2026.

Qualitas Ltd (ASX: QAL)

The Qualitas share price is down 34% over 12 months. 

Gardner has a sell recommendation on this ASX financial share. 

He commented:

Qualitas is an alternative real estate investment manager with about $11.6 billion of committed funds under management at June 30, 2026.

QAL manages investments across real estate private credit and real estate private equity via a range of investment solutions for institutional, wholesale and retail clients.

The company has exposure to construction lending in a sector we believe is under pressure from rising costs amid potentially higher interest rates.

The shares have fallen from $3.36 on August 13 to trade at $2.38 on September 24.

We would rather be on the sidelines until credit costs stop rising.

The post Buy, hold, sell: Telix Pharmaceuticals, Qualitas, Greatland Resources shares appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• 2 ASX shares UBS says could increase 13% to 37%
• 5 ASX 200 shares upgraded by experts this week
• Buy, hold, sell: New Hope, REA, Telix Pharmaceuticals shares
• 5 buy-rated shares in the ASX real estate sector to consider

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Qualitas and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

I think long-term investing in ASX shares is the best approach because it gives our investments time to successfully execute business plans and lets the magic of compounding play out.

The investments I’m going to talk about have already demonstrated their strategies are working and I’m expecting plenty more success in the years ahead.

The first is one of the ASX’s leading exchange-traded funds (ETFs) and the second is a business exposed to one of Australia’s longest-term tailwinds.

Betashares Nasdaq 100 ETF (ASX: NDQ)

This investment gives investors exposure to 100 of the largest non-financial companies on the NASDAQ. The NASDAQ is home to many of the world’s leading technology businesses, so investors are getting significant exposure to tech businesses that are changing the world.

On 24 September 2026, its biggest positions were Nvidia, Apple, Alphabet, Microsoft, Micron Technology, Advanced Micro Devices, Amazon.com and Meta Platforms.

It’s hard to say how the world will change from here, but I imagine technology will remain a key driver of change. New products and services can unlock earnings and expand existing revenue streams, like cloud computing and online shopping.

By the way, I’m calling this an ASX share because it’s about investing in shares and we can buy it on the ASX.

The NDQ ETF holdings continue to see earnings growth, which can drive their share prices higher, which is a big tailwind for the returns of the NDQ ETF.

Impressively, the NDQ ETF has returned an average of 19.4% per year since inception in May 2025. In the past five years, it has returned an average of 14.2% per year. Of course, past performance is not a guarantee of future returns.

Over the next decade, I expect this collective group to continue delivering pleasing earnings growth, probably stronger than the overall global share market. Great businesses have a habit of continuing to deliver good performance.

Propel Funeral Partners Ltd (ASX: PFP)

Propel is the other ASX share I want to highlight. It is the second-largest funeral operator in Australia and New Zealand. Propel operates from 213 locations, including 42 cremation facilities and nine cemeteries.

Australia and New Zealand both have growing and ageing demographics, which means there’s a tailwind for funeral volumes.

According to Propel and the Australian Bureau of Statistics (ABS), the number of deaths in Australia is projected to increase at a compound annual growth rate (CAGR) of 2.8% between 2026 and 2035 and then rise at a CAGR of a further 2.3% between 2036 to 2045.

FY26 was thankfully a challenging year for funeral volumes, with funeral volumes contracting by around 2%. To me, that suggests that funeral volumes are likely to be stronger in the medium term.

Funeral prices are steadily rising over time, which is another tailwind for revenue. In FY26, the average revenue per funeral was $6,673 – a comparable rise of 2% year-over-year.

The company is steadily expanding its geographic presence and scale, which should provide advantages in the coming years. Since FY26, it has deployed around $12 million on five acquisitions in New Zealand.

In July 2026, the first month of FY27, comparable average revenue per funeral rose 3%, and funeral volumes remained resilient despite the lowest recorded winter flu season in five years.

With Propel Funeral Partners’ share price down 45% over the past year, it looks like a great time to be brave and invest.

The post 2 top ASX shares to buy and hold for the next decade appeared first on The Motley Fool Australia.

More reading

• Own US ETFs like IVV or NDQ? Here’s why your dividends are so low
• 10 top ASX ETFs to watch in 2027
• Want to invest in AI? Here are the best ASX ETFs for 2027
• 3 reasons I’d invest $10,000 into the NDQ ETF
• 5 ASX ETFs for Aussie investors to buy and hold for 20 years

Motley Fool contributor Tristan Harrison has positions in Propel Funeral Partners. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Alphabet, Amazon, Apple, BetaShares Nasdaq 100 ETF, Meta Platforms, Micron Technology, Microsoft, and Nvidia. The Motley Fool Australia has positions in and has recommended BetaShares Nasdaq 100 ETF. The Motley Fool Australia has recommended Alphabet, Amazon, Apple, Meta Platforms, Microsoft, and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.